GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poxel SA (XPAR:POXEL) » Definitions » FCF Margin %

Poxel (XPAR:POXEL) FCF Margin % : -1,442.64% (As of Dec. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Poxel FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Poxel's Free Cash Flow for the six months ended in Dec. 2022 was €-8.53 Mil. Poxel's Revenue for the six months ended in Dec. 2022 was €0.59 Mil. Therefore, Poxel's FCF Margin % for the quarter that ended in Dec. 2022 was -1,442.64%.

As of today, Poxel's current FCF Yield % is 0.00%.

The historical rank and industry rank for Poxel's FCF Margin % or its related term are showing as below:

XPAR:POXEL' s FCF Margin % Range Over the Past 10 Years
Min: -3239.76   Med: 0   Max: 0
Current: -3239.76


XPAR:POXEL's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -145.04 vs XPAR:POXEL: -3239.76


Poxel FCF Margin % Historical Data

The historical data trend for Poxel's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poxel FCF Margin % Chart

Poxel Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.23 -97.17 -382.46 -126.46 -3,239.76

Poxel Semi-Annual Data
Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,598.85 -121.27 -686.18 -16,036.14 -1,442.64

Competitive Comparison of Poxel's FCF Margin %

For the Biotechnology subindustry, Poxel's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poxel's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poxel's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Poxel's FCF Margin % falls into.



Poxel FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Poxel's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-21.836/0.674
=-3,239.76 %

Poxel's FCF Margin for the quarter that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=-8.526/0.591
=-1,442.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poxel FCF Margin % Related Terms

Thank you for viewing the detailed overview of Poxel's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Poxel (XPAR:POXEL) Business Description

Traded in Other Exchanges
Address
259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

Poxel (XPAR:POXEL) Headlines

No Headlines